Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
TGF-β/Smad inhibitors block transforming growth factor beta (TGF-β) signaling at its receptor kinases or Smad proteins. TGF-β binds a type II receptor kinase, which then phosphorylates the type I receptor, activin receptor-like kinase 5 (ALK5). The activated type I receptor phosphorylates Smad2 and Smad3, which join Smad4 and move into the nucleus to regulate transcription. SB 431542 and A 83-01 inhibit ALK5 together with the related receptors ALK4 and ALK7. RepSox and galunisertib also target the TGF-β type I receptor, while SIS3 blocks Smad3 downstream. LDN193189 instead inhibits ALK2 and ALK3, type I receptors for bone morphogenetic proteins.
Nicousamide is a potent TGF-β receptor II inhibitor that effectively prevents phosphorylation of this receptor. This compound is instrumental in investigating renal fibrosis and its underlying mechanisms, particularly in animal models of diabetic nephropathy. Researchers can utilize Nicousamide to explore therapeutic strategies aimed at mitigating fibrotic processes in kidney disease.
Out of stock
All 3 sizes